Avidity Biosciences Inc. (NASDAQ:RNA) is one of 15 stocks with the biggest hedge fund momentum, after gaining 28 hedge fund holders during the fourth quarter of 2025. On February 23, Avidity Biosciences Inc. (NASDAQ:RNA) adjourned its special stockholder meeting scheduled for the same day and moved the date to February 26. Avidity Biosciences Inc. (NASDAQ:RNA) said it needs additional time to satisfy conditions for the distribution of all outstanding shares of Atrium Therapeutics Inc. to Avidity stockhol ...

Core Insights - Novartis is acquiring Avidity Biosciences for approximately $12 billion in cash to enhance its RNA-based disease-fighting pipeline [2][3] - Avidity shareholders will receive $72 per share, representing a 46.5% premium over Avidity's closing price prior to the announcement [2][6] - The acquisition will provide Novartis access to three late-stage experimental treatments for serious genetic neuromuscular diseases, utilizing Antibody Oligonucleotide Conjugates (AOC) [3][4] Company Impact - The deal is expected to close in the first half of next year and is projected to increase Novartis's sales compound annual growth rate from 5% to 6% for the period of 2024 to 2029 [4] - Avidity's stock surged over 40% following the announcement, reflecting strong market interest in RNA therapeutics [2][6] - Dyne Therapeutics, another company in the RNA therapy space, also saw its shares rise significantly, indicating a broader positive sentiment in the sector [5][6] Industry Context - The acquisition highlights the growing investor and industry interest in RNA therapeutics, particularly for neuromuscular diseases [3] - Novartis's commitment to innovative and targeted therapies is reinforced by this strategic acquisition, aiming to address progressive neuromuscular diseases [4]